Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 1.5 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 3 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 4.5 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 6 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

United States - English - NLM (National Library of Medicine)

sandoz inc - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson’s disease. rivastigmine tartrate is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] . - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . pregnancy category b there are no adequate and well-controlled studies in pregnant women. reproduction studies conducted in pregnant rats and rabbits at oral doses up to 2.3 mg-base/kg/day, or 2 (rat) and 4 (rabbit) times the maximum recommended hu

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate is contraindicated in patients with:   - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11) ]  - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2) ] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2) ]. risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2 to 4 times the

United States - English - NLM (National Library of Medicine)

apotex corp. - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2-4 times the maximu

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson’s disease. rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)]. - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)]. isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . pregnancy category b   there are no adequate and well-controlled studies in pregnant women. reproduction studies conducted in pregnant rats and rabbits at oral doses up to 2.3 mg-base/kg/day, or 2 (rat) and 4 (rabbit) times the maximum r

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg (equivalent: rivastigmine, qty 6 mg) - capsule, hard - excipient ingredients: iron oxide red; magnesium stearate; microcrystalline cellulose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; hypromellose; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; allura red ac; povidone; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg (equivalent: rivastigmine, qty 4.5 mg) - capsule, hard - excipient ingredients: sodium lauryl sulfate; titanium dioxide; iron oxide red; magnesium stearate; hypromellose; gelatin; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose; propylene glycol; ethanol; isopropyl alcohol; shellac; povidone; tert-butyl alcohol; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.